FindImmune
Private Company
Total funding raised: $2.5M
Overview
FindImmune is a private, preclinical-stage biotech developing novel immuno-oncology therapies. Its core strategy involves stimulating the immune system for anticancer vaccination and overcoming tumor resistance by modulating the tumor microenvironment, particularly through targeting macrophage checkpoints. As a spin-off from the prestigious Gustave Roussy institute, it benefits from deep scientific expertise and a partnered discovery platform. The company is pre-revenue and aims to advance its lead candidates into the clinic to address significant unmet needs in oncology.
Technology Platform
A drug discovery research platform focused on identifying novel therapies that manipulate patented macrophage immune checkpoints, aiming to stimulate anti-cancer immunity and convert 'cold' tumors to 'hot'.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
FindImmune competes in the crowded and fast-moving immuno-oncology space, where numerous companies are developing therapies to modulate the tumor microenvironment and combine with checkpoint inhibitors. Its direct competitors include other biotechs focused on targeting tumor-associated macrophages (TAMs), such as those developing CSF-1R inhibitors, CD47 blockers, and other novel checkpoint modulators.